Form 8-K BIOSPECIFICS TECHNOLOGIE For: Dec 22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Biospecifics (BSTC) Receives Positive CHMP Opinion for XIAPEX; Aegis Capital Comments
December 23, 2014 12:32 PM ESTAegis Capital offered commentary on Biospecifics Technologies (NASDAQ: BSTC) following news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of XIAPEX for the treatment of adult men with Peyronie's disease with a palpable plaque and a curvature deformity of at least 30 degrees at the start of therapy.
Analyst Yi Chen commented, BioSpecifics Technologies announced yesterday... More



